Frontier Biotechnologies

Frontier Biotechnologies, established in 2013, is a commercial-stage biopharmaceutical firm headquartered in Nanjing, China, that focuses on the discovery, development, and commercialization of medicines for unmet medical needs. The company was founded by a group of scientists trained in the United States, including Dr. Dong Xie, who serves as the Chairman, President, and Chief Scientific Officer. Dr. Xie holds a Ph.D. from Johns Hopkins University and brings extensive experience to the company's leadership.

The company's business model is centered on a cross-Pacific approach to drug development, leveraging China's large patient population and growing pharmaceutical market to advance its product pipeline. Frontier Biotechnologies went public in 2020, listing on the Science and Technology Innovation Board of the Shanghai Stock Exchange (stock code: 688221.SH). Its revenue is generated through the sale of its approved pharmaceutical products. The company has established a robust commercial team to market its flagship product in China and several emerging markets, securing its inclusion in China's National Reimbursement Drug List.

Frontier's lead product is Aikening® (Albuvirtide), the world's first long-acting injectable HIV fusion inhibitor. It works by blocking HIV from entering and infecting immune system cells. Approved in China in 2018, Aikening® is used in combination with other antiretroviral drugs for patients who have developed resistance to other treatments. It is administered weekly via intravenous infusion, offering a different treatment paradigm compared to daily oral medications. The company has received marketing authorizations for Aikening® in several other countries, including Ecuador, Cambodia, and Kazakhstan. Beyond its lead product, Frontier Biotechnologies is advancing a diversified pipeline of clinical assets targeting conditions such as osteoporosis, pain management, IgA nephropathy, and hyperuricemia.

Keywords: biopharmaceutical, HIV treatment, long-acting injectable, fusion inhibitor, Albuvirtide, Aikening, drug development, clinical stage, China pharmaceutical market, public company, SHSE:688221, peptide drug platform, antiviral, osteoporosis, pain management, cross-Pacific model, innovative medicines, National Reimbursement Drug List, treatment-experienced patients